









Markets
/
Stocks
/
nasdaq-lnth
/

Lantheus Holdings Inc

LNTH

64.890USD

+0.030+0.05%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

4.30BMarket Cap

26.34P/E TTM



Lantheus Holdings Inc

64.890

+0.030+0.05%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Lantheus Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Lantheus Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 12 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 83.46.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Lantheus Holdings Inc's Score

Industry at a Glance

Industry Ranking

12 / 205

Overall Ranking

82 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Lantheus Holdings Inc Highlights

StrengthsRisks

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 64.04% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.53B.

Overvalued

The company’s latest PE is 26.34, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 71.74M shares, decreasing 17.83% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 32.60K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.29.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

83.462

Target Price

+28.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Lantheus Holdings Inc is 8.53, ranking 38 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 384.01M, representing a year-over-year increase of 1.39%, while its net profit experienced a year-over-year increase of 78.82%.

Score

Industry at a Glance

Previous score

8.53

Change



Financials

8.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.43

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.21

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.27

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Lantheus Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Lantheus Holdings Inc is 8.80, ranking 5 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 26.34, which is 667.55% below the recent high of 202.19 and 1536.58% above the recent low of -378.42.

Score

Industry at a Glance

Previous score

8.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Lantheus Holdings Inc is 8.00, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 77.00, with a high of 130.00 and a low of 60.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

83.462

Target Price

+28.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Lantheus Holdings Inc

LNTH

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Lantheus Holdings Inc is 6.38, ranking 152 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 68.27 and the support level at 62.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.42

Change

-0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.797

Neutral

RSI(14)

43.477

Neutral

STOCH(KDJ)(9,3,3)

21.823

Neutral

ATR(14)

2.213

Low Volatility

CCI(14)

-165.358

Sell

Williams %R

73.928

Sell

TRIX(12,20)

0.010

Sell

StochRSI(14)

2.247

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

65.636

Sell

MA10

66.378

Sell

MA20

66.347

Sell

MA50

65.195

Sell

MA100

59.587

Buy

MA200

66.795

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Lantheus Holdings Inc is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 108.19%, representing a quarter-over-quarter decrease of 9.14%. The largest institutional shareholder is The Vanguard, holding a total of 6.67M shares, representing 10.06% of shares outstanding, with 0.39% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

7.29M

-2.78%

Janus Henderson Investors

6.68M

-3.66%

The Vanguard Group, Inc.

Star Investors

6.92M

+1.47%

Morgan Stanley & Co. LLC

3.68M

+635.59%

Farallon Capital Management, L.L.C.

3.48M

+4.85%

Fidelity Management & Research Company LLC

3.10M

-24.93%

State Street Investment Management (US)

2.50M

-2.41%

Geode Capital Management, L.L.C.

1.75M

-1.26%

Dimensional Fund Advisors, L.P.

1.37M

-0.87%

Reinhart Partners, LLC

1.35M

-3.98%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lantheus Holdings Inc is 7.73, ranking 32 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is -0.08. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Lantheus Holdings Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.